Foxp1, Notch, and Valvular Calcification in CKD
2026-09-07
A 2026 Biochemical Pharmacology study identifies endothelial Foxp1 as a suppressor of chronic kidney disease-associated valvular calcification. Using endothelial-specific Foxp1 overexpression, the authors connect Jagged-1/Notch inhibition with reduced endothelial-to-mesenchymal transition, lower TGF-β1 signaling, improved endothelial integrity, and less osteogenic activation of valvular interstitial cells.
Dihydroartemisinin: Practical Research Workflows
2026-09-05
Build reproducible malaria, mTOR, inflammatory, and psoriasis research assays with a defined small-molecule preparation workflow. This guide connects formulation control, stage-aware parasite testing, cell-proliferation readouts, and troubleshooting while separating evidence for Dihydroartemisinin from findings reported for related compounds.
Thioguanine A4176: Reliable Assay Workflows
2026-09-05
This scenario-driven guide explains how Thioguanine (SKU A4176) can support reproducible cell viability, proliferation, and antiviral workflows. It covers solubility, concentration-response design, data interpretation, and practical vendor-selection criteria for 6-thioguanine experiments.
0.4% Trypan Blue Solution: Practical Cell Viability
2026-09-04
0.4% Trypan Blue Solution provides a direct way to distinguish unstained viable cells from blue-stained cells with damaged membrane integrity during cell counting and viability workflows. It is intended for scientific research, including cell culture and cytotoxicity assays, and must not be used for diagnostic, clinical, or medical purposes.
LY-411575: Designing Dual-Pathway Assays
2026-09-04
Explore how LY-411575, a potent gamma-secretase inhibitor, can be used to distinguish amyloid precursor protein processing from Notch pathway effects. This article translates a key synaptic-transmission study into a rigorous framework for Alzheimer’s disease and cancer research assays.
BRD4–RAC1 Co-targeting in Breast Cancer
2026-09-03
The reference study shows that combined BRD4 and RAC1 inhibition suppresses growth, stemness, migration, and tumorigenesis across breast cancer subtypes by disrupting the c-MYC–G9a–FTH1 axis and reducing HDAC1-associated chromatin regulation. Its findings provide a mechanistic framework for studying how oncogenic signaling and epigenetic control converge in breast cancer models.
Isorhamnetin Oocyte Stress Assay Workflow
2026-09-03
Build a mechanism-led Isorhamnetin workflow for oocyte maturation, oxidative stress, apoptosis, and endoplasmic reticulum stress studies. This guide connects solvent control, concentration selection, phenotype scoring, and PI3K/Akt validation so researchers can distinguish pathway-dependent protection from nonspecific assay effects.
Catalpol Restores the Neurovascular Unit After Stroke
2026-09-02
The reference study shows that Catalpol improves neurological outcomes and neurovascular unit integrity in a rat ischemic stroke model by coordinating VEGF, PI3K/AKT, and MEK1/2/ERK1/2 signaling. Its main practical contribution is an integrated, multicellular framework for neuroprotection research rather than a neuron-only mechanism, supported by both MCAO animals and a three-dimensional in vitro neurovascular unit model.
O-GlcNAcylation, Glycolysis, and Wnt-Driven Bone Formation
2026-09-02
The reference study identifies O-GlcNAcylation as a causal metabolic effector of Wnt-stimulated osteoblastogenesis rather than a passive marker of glucose flux. Its mechanistic model links early Ca2+-PKA-GFAT1 signaling and sustained Wnt-β-catenin activity to O-GlcNAc modification of PDK1, increased aerobic glycolysis, bone formation, and fracture repair.
TJP3, Anoikis, and Breast Cancer Drug Resistance
2026-09-01
The reference study integrates anoikis-related gene profiling, machine-learning prognosis modeling, immune analysis, and experimental validation to identify breast cancer subgroups with distinct outcomes and treatment-response patterns. Its central mechanistic result is that TJP3 is associated with paclitaxel tolerance, migratory behavior, and an immune-evasion phenotype, although prospective clinical validation remains necessary.
Malate as a Causal Probe of Tumor Metabolism
2026-08-31
Malate and (S)-2-hydroxysuccinic acid provide a precise way to interrogate TCA-cycle flux, mitochondrial redox balance, and metabolic–immune signaling. This article develops an assay strategy that distinguishes substrate effects from PDHA1-driven metabolite accumulation in cholangiocarcinoma research.
Standardized Whole-Blood Stimulation in Immunometabolism
2026-08-31
This protocol paper presents a standardized whole-blood stimulation workflow for testing how metabolic interventions reshape cytokine responses to immune and microbial stimuli. Its main practical contribution is a structured assay framework that preserves the complexity of human blood while enabling controlled analysis of immunometabolic regulation in cohort studies.
Gefitinib (ZD1839): EGFR Inhibition Guide
2026-08-30
Gefitinib, also called ZD1839, is an orally bioavailable EGFR tyrosine kinase inhibitor that blocks ATP-site signaling. Its research value is strongest in EGFR-dependent cancer models, where pathway suppression can reduce proliferation and promote G1 arrest or apoptosis under defined experimental conditions.
Pomalidomide Workflows for Myeloma Research
2026-08-29
Pomalidomide (CC-4047) supports more than single-agent viability testing: it can connect cytokine suppression, tumor microenvironment modulation, genotype-aware screening, and erythroid progenitor cell differentiation. This practical workflow shows how to formulate, dose, interpret, and troubleshoot CC-4047 experiments in hematological malignancy research.
Deferasirox: Oral Chelation Evidence and Methods
2026-08-29
This formulary review synthesized the pharmacology, clinical evidence, tolerability, and economic considerations surrounding deferasirox as an oral alternative to parenteral deferoxamine for transfusional iron overload. Its main contribution was to connect ferric iron chelation and treatment adherence with practical decision-making across beta-thalassemia, sickle cell disease, myelodysplastic syndrome, and other chronic anemias.
459 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page